---
name: Weikun Qu
image: images/weikun_qu.jpg
role: member
aliases:
  - 曲卫昆老师
links:
  email:
---

曲卫昆，副教授，医学博士，中共党员，肝胆外科副主任医师、硕士研究生导师，现任大连医科大学研究生院副院长，大连医科大学附属第二医院OPO办公室主任（器官捐献与获取相关工作），兼任器官捐献管理办公室及区域医疗发展部管理岗位，长期从事器官捐献协调与移植相关临床管理和学科建设工作。学术兼职包括：中华医学会器官移植分会捐献与获取学组委员、中国医院协会器官捐献与移植专委会委员、辽宁省医学会器官移植分会常务委员等。
科研方面坚持以临床问题为导向、以机制研究支撑转化的思路，2013年以来持续开展肝胆与肾脏疾病的基础与转化研究，注重从临床实际出发提出科学问题，力求从机制发现转化为临床诊治策略；2017年取得国家器官捐献协调员资格证。当前研究聚焦于肝肾损伤与修复及其相关的系统性炎症反应，覆盖器官移植、炎症免疫、肿瘤与转化医学等方向。近年来已在相关领域发表多篇SCI论文，并取得多项专利成果。
主持省级课题1项，大连市课题1项，横向课题1项，参与国家自然基金1项，省级课题1项（第2位），个体化诊疗协同创新中心联合基金1项（第2位）。已发表SCI论文8篇，获发明专利2项。
邮箱：qwkgdwk@126.com
Weikun Qu, MD, Associate Professor and master’s supervisor, is a Deputy Chief Physician in the Department of Hepatobiliary Surgery and a member of the Communist Party of China. He currently serves as Director of the Organ Procurement Organization (OPO) Office at the Second Affiliated Hospital of Dalian Medical University, and concurrently holds management roles in the Organ Donation Administration Office and the Regional Healthcare Development Department. He has long been engaged in the clinical administration, discipline development, and capacity building related to organ donation coordination and transplantation.
His academic appointments include Member of the Donation and Procurement Group, Organ Transplantation Branch of the Chinese Medical Association; Member of the Organ Donation and Transplantation Professional Committee, Chinese Hospital Association; and Standing Committee Member of the Organ Transplantation Branch, Liaoning Medical Association, among others.
In research, Dr. Qu adheres to a clinically driven approach supported by mechanistic studies to facilitate translational application. Since 2013, he has continuously conducted basic and translational research on hepatobiliary and renal diseases, emphasizing clinically relevant scientific questions and aiming to translate mechanistic discoveries into practical diagnostic and therapeutic strategies. In 2017, he obtained the National Qualification Certificate for Organ Donation Coordinators. His current research focuses on hepatorenal injury and repair and the associated systemic inflammatory responses, spanning organ transplantation, inflammation and immunity, oncology, and translational medicine. In recent years, he has published multiple SCI-indexed papers in related fields and obtained several patents.
He has led one provincial-level project, one Dalian municipal project, and one industry-sponsored project, and has participated in one National Natural Science Foundation of China (NSFC) project, one provincial-level project (second contributor), and one Joint Fund project of the Collaborative Innovation Center for Personalized Diagnosis and Treatment (second contributor). He has published 8 SCI papers and has been granted 2 invention patents.
Email: qwkgdwk@126.com
课题项目情况：
1.项目名称：巨噬细胞CMPK2在脓毒症引起急性肾损伤中的作用及机制研究 项目编号：2025-BSLH-112；辽宁省科技计划联合计划；2025.11-2027.10；5万元 主持
2.项目名称：榄香烯逆转肝癌细胞索拉菲尼耐药机制的研究 项目编号：1812039；大连市科技局；2018.01-2020.12；2万元 主持
3.项目名称：卡瑞丽珠单抗治疗晚期肝癌的前瞻性、开放性、多中心的真实世界研究 项目编号：YXJL-2022-0435-0089；北京医学奖励基金会；2022.10-2023.9；10元 主持
4.项目名称：探究CES2在乳腺癌中的作用并构建其靶向荧光探针辅助乳腺癌精准诊疗的实验研究 项目编号：XJ2023000401;辽宁省自然基金院内培育项目2023.3-2024.2；3万元 主持
5.项目名称：辽宁省大连医科大学第二医院1+X临床技术改进 项目编号：2024LCJSYL03；大连医科大学第二医院自然医院培育项目；10万元 主持
6.项目名称：大黄素调节内质网应激介导的NLRP3活化对重症胰腺炎所致肺损伤的干预机制研究项目编号：81773966；国家自然科学基金面上项目；2019.1-2021.12；55万元 参与
7.项目名称：基于ATM/ATR/RAD51信号通路靶向MET蛋白增强PARP抑制剂在mCRPC中的作用机制研究项目编号：2022-MS-316; 省自然科学基金；2022.9-2014.8；5万元 参与（第2位）
8.项目名称：基于代谢组学筛选物DHA在原发性青光眼中分子机制及临床研究 项目编号：dy2yhws201805；个体化诊疗协同创新中心联合基金；2021.1-2023.12；20万元 参与（第2位）
9.项目名称：基于ATM/ATR/RAD51信号通路靶向MET蛋白增强PARP抑制剂在mCRPC中的作用机制研究项目编号：2022-MS-316；省自然科学基金；2022.9-2014.8；5万元 参与（第2位）
发表论著：
Qu, W., et al. (2022). Highly biocompatible apigenin-loaded silk fibroin nanospheres: Preparation， characterization， and anti-breast-cancer activity. Polymers, 15 (1), 23. (IF:5.0)
Qu, W., et al. (2023). Prognostic and Immunological Roles of CES2 in Breast Cancer and Potential Application of CES2-Targeted Fluorescent Probe DDAB in Breast Surgery. International Journal of General Medicine, 1567-1580. (IF:2.3)
Wang, S., ..., Qu, W. K., & Li, H. H. (2022). CXCL1-CXCR2 signalling mediates hypertensive retinopathy by inducing macrophage infiltration. Redox Biology, 56, 102438. (IF:10.6)
Wang, S., ..., Qu, W. K., & Li, J. (2023). Fucoidan inhibits apoptosis and improves cardiac remodeling by inhibiting p53 transcriptional activation through USP22/Sirt 1. Frontiers in Pharmacology, 14, 1164333. (IF:5.9)
Liu, Y., Pan, B., Qu, W., Cao， Y., Li, J., & Zhao, H. (2021). Systematic analysis of the expression and prognosis relevance of FBXO family reveals the significance of FBXO1 in human breast cancer. Cancer Cell International, 21(1), 1-25. (IF:6.43)
Gao, Z., Sui, J., Fan, R., Qu, W., Dong, X., & Sun, D. (2020). Emodin protects against acute pancreatitis-associated lung injury by inhibiting NLPR3 inflammasome activation via Nrf2/HO-1 signaling. Drug design, development and therapy, 1971-1982. (IF:4.16)
Dong, C., Liu, Y., Jiang, K., Wang, H., Qu, W., Zhang, C., & Wang, L. (2018). The Nogo‐B receptor promotes human hepatocellular carcinoma cell growth via the Akt signal pathway. Journal of cellular biochemistry， 119(9), 7738-7746. (IF:4.2)
Shao, P., Qu, W. K., Wang, C. Y., Tian, Y., Ye, M. L., Sun, D. G., & Gao, Z. M. (2017). MicroRNA-205-5p regulates the chemotherapeutic resistance of hepatocellular carcinoma cells by targeting PTEN/JNK/ANXA3 pathway. American Journal of Translational Research, 9(9), 4300. (IF:3.38)
发明专利：
1. 王帅 张智健 张洋 卫皇曌 曲卫昆：一种基于药液和穴位磁疗的眼罩 专利号：202320702886.9
2. 王帅 卫皇曌 荣欣 白洁 曲卫昆 万茜 姚晨星：器官维护仪（小动物） 专利号：202330567158.7
